Journal club

Menzies-Gow et al (N Engl J Med, 2021, DOI: 10.1056/NEJMoa2034975) investigated the impact of tezepelumab on patients with asthma already established on medium-dose or high-dose inhaled corticosteroids and two exacerbations in the previous year in a phase 3, multicentre, randomised, double-blind, pl...

Full description

Saved in:
Bibliographic Details
Published inThorax Vol. 76; no. 12; p. 1266
Main Author Vijayakumar, Bavithra
Format Journal Article
LanguageEnglish
Published London BMJ Publishing Group LTD 01.12.2021
Subjects
Asthma
Chronic obstructive pulmonary disease
COVID-19
Inflammation
Patients
Steroids
Online AccessGet full text

Cover

More Information
Summary:Menzies-Gow et al (N Engl J Med, 2021, DOI: 10.1056/NEJMoa2034975) investigated the impact of tezepelumab on patients with asthma already established on medium-dose or high-dose inhaled corticosteroids and two exacerbations in the previous year in a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. [...]although the clinical utility of this approach needs to be tested to ensure patient outcomes are maintained, it may enable more focused use of steroids and antibiotic therapy and is an important step towards personalised medicine in patients with difficult asthma. Corren et al conducted a post-hoc analysis of 1902 patients (dupilumab n=1264, placebo n=638) from this phase 3 study (Eur Respir J 2021 DOI: 10.1183/13993003.04498-2020) examining exacerbation frequency, lung function and quality of life stratified by markers of T2 inflammation (eosinophil count, inhaled corticosteroid dose and FeNO).
ISSN:0040-6376
1468-3296
DOI:10.1136/thoraxjnl-2021-218369